Type 1 Diabetes Clinical Trial
Official title:
FAM (Follower, Action Plan, and Remote Monitoring) Intervention to Reduce Severe Hyperglycemia in Adults With Type 1 Diabetes Mellitus at Risk for Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA) results in significant morbidity and healthcare utilization and is the main contributor to loss of life expectancy in people with diabetes mellitus type 1 (T1DM) <50 years old. This suggests the need to develop interventions to reduce DKA events. Innovative features of newer continuous glucose monitoring devices offer opportunities for novel strategies to reduce DKA. Designating a family member, friend, or caregiver as a Follower was associated with reduction in HbA1C, increased time in range, and improvement in quality of life metrics in people with T1DM. However, the previously published studies are limited as they were either retrospective, survey-based, or do not overlap with our proposed cohort involving adults ages 18-65 with T1DM (prior prospective studies involved either pregnant women with T1DM or adults ≥60 years of age with T1DM). This study is a randomized controlled trial pilot study to evaluate the effectiveness of an intervention (FAM) using a Follower, Action Plan, and Remote Monitoring of glucose data to reduce severe hyperglycemia, a modifiable risk factor for DKA, in adults with T1DM at high risk for DKA. The intervention uses real-time glucose data sharing with a Follower (family member, friend, or caregiver) and personalized diabetes education provided to the dyad (person with T1DM and their chosen Follower). The study hypothesizes that the FAM intervention will reduce the percentage of time spent with glucose ≥250 mg/dL compared to standard care alone.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - People with T1DM for =1 year ages 18 - 65 - HbA1C =7.5.0% - 14.0% - If the person with T1DM uses a CGM, the CGM must have the capability of real-time data sharing including glycemic alerts with a Follower (including but not limited to Dexcom G6 or G7 or FreeStyle Libre 2 or 3, or Medtronic Guardian Sensor 3) - Follower (family member or friend ages 18 years and older) willing to participate in the study and "follow" glucose data and who was no self-reported cognitive impairment - Ability of the dyad (participant and Follower) to communicate and provide consent in English - CGM users: =50% personal CGM use and =50% Dexcom G6 Pro CGM use during the pre-intervention period (days -14 to -1) - Non CGM users: =50% Dexcom G6 Pro CGM use and average =2 BGM readings/day during the pre-intervention period (days -14 to -1) Exclusion Criteria: - Prisoner - Active treatment with a sodium-glucose cotransporter-2 inhibitor or planning to start a sodium-glucose cotransporter-2 inhibitor in the next 6 months - Active malignancy with the exception of non-melanoma skin cancer - Hospice - Skin conditions that inhibit wearing a CGM sensor and known severe allergy to adhesives |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Hospitalization for DKA | -The number of DKA-related hospitalizations for each participant will be recorded | 90 days | |
Primary | percentage of time with severe hyperglycemia | number of continuous glucose monitoring or blood glucose monitoring readings with glucose =250 mg/dL divided by the total number of readings | 90 days | |
Secondary | Hyperglycemia - Continuous Glucose Monitor glucose monitor (CGM) metrics | -Percentage of time glucose >180 mg/dL | 90 days | |
Secondary | Severe hyperglycemia >400 mg/dL - Continuous Glucose Monitor glucose monitor (CGM) metrics | -Percentage of time glucose >400 mg/dL | 90 days | |
Secondary | Hypoglycemia - continuous glucose monitor | -Percentage of time glucose< 70 mg/dL | 90 days | |
Secondary | Hemoglobin A1c | -HbA1c | days 0 and 90 | |
Secondary | Level 2 Hypoglycemia - Continuous Glucose Monitor | -Percentage of time glucose < 54 mg/dL | 90 days | |
Secondary | Time in Range - Continuous Glucose Monitor | -Percentage of time glucose is 70 - 180 mg/dL | 90 days | |
Secondary | Glycemic variability - Continuous Glucose Monitor | -Glycemic variability | 90 days | |
Secondary | Glucose Management Indicator - Continuous Glucose Monitor | -Glucose Management Indicator | 90 days | |
Secondary | Number of glucose reading/day - Blood Glucose Monitor | -Number of glucose readings/day | 90 days | |
Secondary | Hyperglycemia - Blood Glucose Monitor | -Percentage of time glucose <180 mg/dL | 90 days | |
Secondary | Severe Hyperglycemia > 400 mg/dL - Blood Glucose Monitor | -Percentage of time glucose >400 mg/dL | 90 days | |
Secondary | Hypoglycemia - Blood Glucose Monitor | -Percentage of time glucose< 70 mg/dL | 90 days | |
Secondary | Level 2 Hypoglycemia -Blood Glucose Monitor | -Percentage of time glucose < 54 mg/dL | 90 days | |
Secondary | Time in Range - Blood Glucose Monitor | -Percentage of time glucose is 70 - 180 mg/dL | 90 days | |
Secondary | Ketone assessment | -Frequency and severity of ketonuria assessed using urine ketone test strips | 90 days | |
Secondary | Assessment of the intervention's efficacy and its burden on participants | -Questionnaire | 90 days | |
Secondary | Hypoglycemic Confidence Scale | Likert Scale
Minimum value: Not Confident At All Maximum value: Very Confident |
90 days | |
Secondary | Diabetes Distress Scale for Adults with T1DM | Likert Scale
Minimum value: A Very Serious Problem Maximum value: Not a Problem |
90 days | |
Secondary | Diabetes Empowerment Scale | Likert Scale
Minimum value: Strongly Disagree Maximum value: Strongly Agree |
90 days | |
Secondary | 36-Item Short-Form Health Survey | -Questionnaire | 90 days | |
Secondary | Hypoglycemic Confidence Scale for Partners of Adults with T1DM | Likert Scale
Minimum value: Not Confident At All Maximum value: Very Confident |
90 days | |
Secondary | Diabetes Distress Scale for Partners of Adults with T1DM | Likert Scale
Minimum value: A great deal Maximum value: Not at all |
90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A |